.svg)
.svg)
PARTNER WITH ASCENDIA
ASCENDIA PROVIDES…
- FORMULATION DEVELOPMENT OF POORLY SOLUBLE DRUGS
- CLINICAL MATERIAL MANUFACTURE OF ORAL & PARENTERAL PRODUCTS
- BIOEQUIVALENT DOSAGE FORMS & PRODUCT LIFE-CYCLE MANAGEMENT
Ascendia provides its partners rapid, comprehensive and cost-effective solutions for their difficult formulation development projects. Ascendia provides complete CDMO services from pre-formulation to clinical manufacture.
Ascendia is also seeking co-development partners for our proprietary development programs, and for co-development of challenging ANDA products.
Contact us to start a conversation about how we can collaborate.
WORK WITH US
Business development at Ascendia is focused on our client’s needs. You will find us responsive, thorough, and easy to work with. After gaining a solid understanding of your project’s requirements, we will provide you with a customized proposal. Our goal is consistent with your goal – provide quality service, exceptional insight, timely output and fair pricing. We welcome the opportunity to discuss how we can collaborate to advance your exciting pharmaceutical development project.
OUR MARKET SEGMENTS
Ascendia works with companies to help realize their development objectives. We seek to partner with emerging pharmaceutical companies in need of early-stage formulation development services, generic companies looking for innovative technology, and specialty pharmaceutical companies with ideas for new product development programs.
There are many small pharmaceutical companies that have exciting discoveries – new drug molecules with activity against a selected target. Often these companies have limited expertise in formulation development, and limited time and money to reach clinical proof-of-concept. If your company fits this description, Ascendia can help. We provide pre-formulation data package development, small-scale formulations for conducting toxicology studies and initial in-vivo animal studies, and assessment of likely formulation development options for first in man trials.
As more marketed pharmaceutical dosage forms contain enabling solubilization technologies, the challenge to develop generic versions upon patent expiration increases. Developing bioequivalent dosage forms for such products requires expertise with a large array of solubility enhancing technologies – Ascendia can help. Our sophisticated suite of technologies for working with poorly-soluble molecules gives us an edge in developing the best generic equivalent, especially in the quick-paced environment of generic product development. We develop formulations for oral, topical, and parenteral delivery.
Whether your company is mid-sized, small or virtual, there is frequently a need to access innovative technical approaches for developing new forms of already marketed medicines. A novel nano-emulsion, a new amorphous dosage form, or a reduced particle size formulation may prove instrumental in achieving the goals for a new product development program. If your company has a concept for a new product, but needs enabling technology to make it a reality – Ascendia can help. We develop products for oral controlled release, products for long-acting injection, and many other unique dosage forms. We can tailor development programs to deliver against requirements for a new product without encumbering your intellectual property or slowing down your program.
Want to learn more about
Ascendia's expertise?
Get up-to-date information
